Abstract: The present invention provides nutritional compositions (for example, sensorially acceptable nutritional compositions) that comprise a fruit component, a fiber component, and a micronutrient component. Also provided are methods of making and using the nutritional compositions.

Abstract: The present invention provides nutritional compositions (for example, sensorially acceptable nutritional compositions) that comprise a fruit component, a fiber component, and a micronutrient component. Also provided are methods of making and using the nutritional compositions.

Abstract: The present invention provides nutritional compositions (for example, sensorially acceptable nutritional compositions) that comprise a fruit component, a fiber component, and a micronutrient component. Also provided are methods of making and using the nutritional compositions.

Abstract: The present invention provides nutritional compositions (for example, sensorially acceptable nutritional compositions) that comprise a fruit component, a fiber component, and a micronutrient component. Also provided are methods of making and using the nutritional compositions.

Abstract: A liquid lubricant base oil composition comprising (i) a base stock comprising at least 95% by weight saturated hydrocarbons such as for example a Group II base stock, a Group III base stock and/or a base stock derived from Fischer-Tropsch synthesised, waxy, paraffinic hydrocarbon material and (ii) 0.2 to 30% by weight of an aromatic extract which has a dimethyl sulphoxide extractable polycyclic aromatics content of less than 3 weight % may be made by blending the components together and may be used with one or more additives in a lubricant composition which may be used in applications such as marine engine lubricants.

Abstract: A?-heme peroxidase activity is selectively measured and inhibited, packaged as a pharmaceutical composition with heme biosynthetic cofactors or as an industrial enzyme, and used to oxidize target substrates.

Abstract: A ?-heme peroxidase activity is selectively measured and inhibited, packaged as a pharmaceutical composition with heme biosynthetic cofactors or as an industrial enzyme, and used to oxidize target substrates.

Abstract: In a method of treating hypertension in individuals suffering therefrom, the method includes administering to said individuals an effective amount of carnitine and an effective amount of lipoic acid. A method of treating hypertension in individuals suffering therefrom includes administering twice a day a combination of 500 mg carnitine, 200 mg lipoic acid and optionally 100 micrograms of biotin. A method of treating hypertension in individuals with systolic blood pressure above about 135 mmHg includes administering a combination of carnitine, lipoic acid and optionally biotin.

Abstract: Cell senescence is delayed by contacting a cell specifically determined to be in need of delayed cell senescence with an effective amount of a diaminophenothiazine.

Abstract: The invention is a method for analyzing immature reticulocytes for the presence of micronuclei. The method includes reticulocyte enrichment, fluorescent labeling, micronuclei staining, and analysis using single-laser flow cytometry. The invention also includes kits containing reagents to use in the method.

Abstract: Pharmaceutical nitrone comprise condensates of an N-hydroxylamine and a physiological aldehyde, providing improved delivery and absorption, enhanced stability and reduced toxicity. Preferred physiological aldehydes are subject to endogenous cellular uptake transport, and include pyridoxal, pyridoxal phosphate, and heme-A. Essentially any physiologically compatible and pharmaceutically active hydroxylamine moiety may be incorporated, such as hydroxylamine moieties of prior pharmaceutical nitrones, and known pharmaceutically active hydroxylamines.

Abstract: Anti-inflammatory compositions include medicaments comprising predetermined amounts of a phytyl substituted chromanol and a prostaglandin E2 inhibitor, wherein: said medicament is in unit dosage form suitable for pharmaceutical administration; said phytyl substituted chromanol is a gamma-tocopherol, delta-tocopherol, gamma-tocotrienol or delta-tocotrienol; said PGE2 inhibitor is a non-steroidal anti-inflammatory drug or an omega-3 fatty acid, such as docosahexaenoic acid and eicosapentaenoic acid.